Harmony Biosciences Holdings, Inc. HRMY Business Segments — Net Income Loss

Similar metrics at other companies

ANIPRare Disease and Brands — Operating Income (Loss)

$36.25M+71.5%

ANIPRare Disease and Brands — Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

$36.25M+71.5%

PTCTLife Science — Net Income Loss

-$2.81M-100%

ANIPRare Disease total net revenues — Net Revenues

$94.37M+36.9%

ANIPRare Disease and Brands — Net Revenues

$128.24M+36.3%

AXSMNet Income

-$64.54M-8.6%

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s business segments — net income loss?

Harmony Biosciences Holdings, Inc. (HRMY) reported business segments — net income loss of $32.49M in Q1 2026.

How has Harmony Biosciences Holdings, Inc.'s business segments — net income loss changed year-over-year?

Harmony Biosciences Holdings, Inc.'s business segments — net income loss decreased by 28.7% year-over-year, from $45.56M to $32.49M.

What is the long-term trend for Harmony Biosciences Holdings, Inc.'s business segments — net income loss?

Over 3 years (2022 to 2025), Harmony Biosciences Holdings, Inc.'s business segments — net income loss has grown at a -4.4% compound annual growth rate (CAGR), from $181.47M to $158.69M.

What does business segments — net income loss mean?

This metric measures the total profitability of the rare neurological diseases segment after accounting for all associated revenues and operating expenses. It serves as the primary indicator of the segment's financial health and its contribution to the overall corporate bottom line. A positive value indicates the segment is self-sustaining and profitable, while a negative value suggests the segment is currently a drain on corporate resources.